Join our daily newsletter At The Bell to receive exclusive market insights
- Amplia Therapeutics (ATX) completes the design for a Phase 2 clinical trial in first-line pancreatic cancer patients
- The clinical trial of its Focal Adhesion Kinase inhibitor, AMP945, will be added to chemotherapy with the standard of care currently used to treat the majority of newly diagnosed pancreatic cancer patients
- In the trial, AMP945 will be administered orally to patients prior to each dose of their standard chemotherapy
- Amplia says it plans to initiate patient recruitment at Australian sites in the first quarter of 2022
- Amplia Therapeutics closed down 2.50 per cent at 19.5 cents
Amplia Therapeutics (ATX) has completed the design for a Phase 2 clinical trial in first-line pancreatic cancer patients.
The clinical trial of its Focal Adhesion Kinase inhibitor, AMP945, will be added to chemotherapy with gemcitabine and nabpaclitaxel – the standard of care currently used to treat the majority of newly diagnosed pancreatic cancer patients.
In the trial, AMP945 will be administered orally to patients prior to each dose of their standard chemotherapy.
The company said conducting the phase 2 clinical trial in first-line patients is expected to expedite recruitment and provide the best opportunity to detect any efficacy signal from the addition of AMP945 to chemotherapy.
“Clinical evaluation of AMP945 as part of a first-line treatment for pancreatic cancer significantly de-risks the program and makes the drug relevant for a much larger patient base.” said Dr John Lambert, CEO of Amplia Therapeutics.
“If we are able to see positive signs that AMP945 improves the leading current treatment option we will commence discussions with regulators and potential partners concerning future trials required to support product approval.”
Amplia says it plans to initiate patient recruitment at Australian sites in the first quarter of 2022, which is expected to take around 18 to 24 months.
Amplia Therapeutics closed down 2.50 per cent at 19.5 cents.
